Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children

Pincez, Thomas; Santiago, Raoul; Bittencourt, Henrique; Louis, Isabelle; Bilodeau, Mélanie; Rouette, Alexandre; Jouan, Loubna; Landry, Josette‐Renée; Couture, Françoise; Richer, Johanne; Teira, Pierre; Duval, Michel; Cellot, Sonia

doi:10.1038/s41409-021-01408-5

Cited by 4 publications

(3 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, detection limits of 1% or less may be warranted in clinical situations such as AML or acute lymphoblastic leukemia (ALL) that otherwise lack an MRD marker. In addition, combining chimerism analysis with MRD detection is a promising option to prevent or treat post-HSCT relapse of hematologic malignancies as early as possible, with interventions including DLI [ 39 , 40 , 41 , 42 , 43 , 44 ]. It should be noted that the presence of recipient chimerism is less specific for the prediction of disease relapse, and it does not necessarily indicate an active hematologic malignancy [ 45 ].…”

Section: Methods Of Chimerism Analysismentioning

confidence: 99%

“…It should be noted that the presence of recipient chimerism is less specific for the prediction of disease relapse, and it does not necessarily indicate an active hematologic malignancy [ 45 ]. Moreover, MRD detection with a sensitive method may precede the emergence of recipient chimerism at a time point prior to clinical relapse [ 39 , 44 ].…”

Section: Methods Of Chimerism Analysismentioning

confidence: 99%

“…Studies evaluating both recipient chimerism and MRD in acute leukemia after allo-HSCT have shown that MRD detection preceded the emergence of >1% recipient chimerism measured by STR-PCR; however, increasing recipient chimerism was associated with relapse [ 41 , 44 ]. A study using qPCR, which is more sensitive than STR-PCR, demonstrated a relapse rate of 55% at 2 years in acute leukemia patients with >1.0% recipient chimerism, whereas no acute leukemia patients with < 1.0% recipient chimerism showed relapse [ 6 ].…”

Section: Chimerism Analysis Guiding Management Of Allo-hsct Recipientsmentioning

confidence: 99%

See 2 more Smart Citations

Prospects and Potential for Chimerism Analysis after Allogeneic Hematopoietic Stem Cell Transplantation

Miura,

Ueda,

Minakawa

et al. 2024

Cells

View full text Add to dashboard Cite

Chimerism analysis after allogeneic hematopoietic stem cell transplantation serves to confirm engraftment, indicate relapse of hematologic malignancy, and attribute graft failure to either immune rejection or poor graft function. Short tandem repeat PCR (STR-PCR) is the prevailing method, followed by quantitative real-time PCR (qPCR), with detection limits of 1–5% and 0.1%, respectively. Chimerism assays using digital PCR or next-generation sequencing, both of which are more sensitive than STR-PCR, are increasingly used. Stable mixed chimerism is usually not associated with poor outcomes in non-malignant diseases, but recipient chimerism may foretell relapse of hematologic malignancies, so higher detection sensitivity may be beneficial in such cases. Thus, the need for and the type of intervention, e.g., immunosuppression regimen, donor lymphocyte infusion, and/or salvage second transplantation, should be guided by donor chimerism in the context of the feature and/or residual malignant cells of the disease to be treated.

show abstract

Section: Methods Of Chimerism Analysismentioning

confidence: 99%

Section: Methods Of Chimerism Analysismentioning

confidence: 99%

Section: Chimerism Analysis Guiding Management Of Allo-hsct Recipientsmentioning

confidence: 99%

See 1 more Smart Citation

Prospects and Potential for Chimerism Analysis after Allogeneic Hematopoietic Stem Cell Transplantation

Miura,

Ueda,

Minakawa

et al. 2024

Cells

View full text Add to dashboard Cite

show abstract

Flexible genosensors based on polypyrrole and graphene quantum dots for PML/RARα fusion gene detection: A study of acute promyelocytic leukemia in children

Oliveira¹,

Avelino²,

Oliveira³

et al. 2023

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation

Tecchio

Russignan²,

Krampera³

2023

Front. Oncol.

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a survival benefit to adult patients affected by acute lymphoblastic leukemia (ALL). However, to avoid an overt disease relapse, patients with pre or post transplant persistence or occurrence of measurable residual disease (MRD) may require cellular or pharmacological interventions with eventual side effects. While the significance of multiparametric flow cytometry (MFC) in the guidance of ALL treatment in both adult and pediatric patients is undebated, fewer data are available regarding the impact of MRD monitoring, as assessed by MFC analysis, in the allo-HSCT settings. Aim of this article is to summarize and discuss currently available information on the role of MFC detection of MRD in adult ALL patients undergoing allo-HSCT. The significance of MFC-based MRD according to sensitivity level, timing, and in relation to molecular techniques of MRD and chimerism assessment will be also discussed.

show abstract

Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children

Cited by 4 publications

References 52 publications

Prospects and Potential for Chimerism Analysis after Allogeneic Hematopoietic Stem Cell Transplantation

Prospects and Potential for Chimerism Analysis after Allogeneic Hematopoietic Stem Cell Transplantation

Flexible genosensors based on polypyrrole and graphene quantum dots for PML/RARα fusion gene detection: A study of acute promyelocytic leukemia in children

Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation

Contact Info

Product

Resources

About